Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

96.46EUR
11:35am EDT
Change (% chg)

€0.00 (+0.00%)
Prev Close
€96.46
Open
€96.65
Day's High
€96.69
Day's Low
€96.11
Volume
322,940
Avg. Vol
468,960
52-wk High
€115.20
52-wk Low
€90.00

Latest Key Developments (Source: Significant Developments)

Merck KGaA to enter into strategic collaboration with Project Data Sphere LLC
Monday, 11 Sep 2017 05:22am EDT 

Sept 11 (Reuters) - MERCK KGAA ::WILL ENTER INTO A STRATEGIC COLLABORATION WITH PROJECT DATA SPHERE LLC.  Full Article

Merck to acquire Natrix Separations
Monday, 28 Aug 2017 08:00am EDT 

Aug 28 (Reuters) - Merck KGaA ::Merck to acquire Natrix Separations to advance next-generation processing capabilities.Merck says the transaction is expected to close in Q3 of 2017; financial details were not disclosed.  Full Article

Merck KGaA to decide over next few mths over U.S. filing of cladribine
Thursday, 3 Aug 2017 04:30am EDT 

Aug 3 (Reuters) - Merck KGaA :CEO says liquid crystal market share now at slightly above 60 percent, to decline to 50-60 percent over next 2 yrs.CEO says to report over next few months whether to seek U.S. Approval for MS drug Mavenclad/cladribine.  Full Article

Merck KGaA says patent office to grant patent application for Crispr
Thursday, 3 Aug 2017 04:27am EDT 

Aug 3 (Reuters) - Merck Kgaa :Says European patent office to grant Merck’s patent application for Crispr technology.Says European patent office has issued a notice of intention to grant for its patent application covering the company’s Crispr technology.Anticipates favourable outcomes in other countries as well.  Full Article

Merck names Kai Beckmann to head Performance Materials business
Thursday, 3 Aug 2017 12:53am EDT 

Aug 3 (Reuters) - Merck KGaA :Kai beckmann to assume responsibility for the performance materials business sector.Walter galinat takes over responsibility for the darmstadt site, procurement as well as environment and quality.  Full Article

Merck KGaA and Pfizer: CHMP recommends approval of avelumab
Friday, 21 Jul 2017 07:38am EDT 

July 21 (Reuters) - MERCK KGAA ::EMA’S CHMP ISSUES POSITIVE OPINION FOR AVELUMAB FOR THE TREATMENT OF METASTATIC MERKEL CELL CARCINOMA.EUROPEAN COMMISSION WILL NOW REVIEW THE CHMP’S RECOMMENDATION, WITH A DECISION EXPECTED IN THE THIRD QUARTER OF 2017‍​.  Full Article

Merck KGaA refines Western European Life Science Production site network
Wednesday, 12 Jul 2017 09:43am EDT 

July 12 (Reuters) - MERCK KGAA ::REFINES WESTERN EUROPEAN LIFE SCIENCE PRODUCTION SITE NETWORK.CURRENT SITE NETWORK IN WESTERN EUROPE WILL BE REFINED, WHILE THE COMPANY INVESTS € 90 MILLION IN FOUR SITES IN GERMANY, SWITZERLAND AND FRANCE.THE OPERATIONS IN STEINHEIM, EPPELHEIM, HOHENBRUNN AND BERLIN (GERMANY) WILL BE RELOCATED AND SEQUENTIALLY CLOSED IN THE COURSE OF 2019 TO 2022.THERE WILL BE A NET IMPACT OF APPROXIMATELY 200 FEWER POSITIONS ACROSS THESE SITES UNTIL 2022.THE EXISTING HAMBURG (GERMANY) SITE WILL CONTINUE TO OPERATE AS BEFORE.  Full Article

EU medicines agency recommends approval of Aveo's kidney cancer drug
Friday, 23 Jun 2017 08:24am EDT 

June 23 (Reuters) - EU Medicines Agency::EU Medicines Agency recommendations for June 2017.EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug.EU Medicines Agency recommends approval of Abbvie hepatitis C combination.EU Medicines Agency recommends approval of Novartis Kisqali drug for breast cancer.EU Medicines Agency recommends approval of Aveo drug for kidney cancer.EU Medicines Agency recommends approval of biosimilar drug by Samsung Bioepis UK for Abbvie's rheumatoid arthritis drug.  Full Article

EMA recommends approval of Merck's multiple sclerosis drug
Friday, 23 Jun 2017 07:43am EDT 

June 23 (Reuters) - EU Medicines Agency::EU Medicines Agency recommendations for June 2017.EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug.EU Medicines Agency recommends approval of Abbvie Hepatitis C combination.EU Medicines Agency recommends approval of Novartis Kisqali drug for breast cancer.EU Medicines Agency recommends approval of Aveo drug for kidney cancer.EU Medicines Agency recommends approval of Abbvie biosimilar drug for rheumatoid arthritis.  Full Article

Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer
Tuesday, 20 Jun 2017 08:00am EDT 

June 20 (Reuters) - Merck Kgaa :Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer.Effector Therapeutics - cos plan to initiate Phase 2 study to evaluate EFT508 in combination with avelumab in microsatellite stable relapsed or refractory CRC patients.Effector Therapeutics - Pfizer and Merck KGAA will share clinical study costs with effector.  Full Article

RPT-UPDATE 1-Germany's Merck hires JP Morgan to sell consumer health

FRANKFURT/LONDON, Sept 8 Germany's Merck KGaA has hired JP Morgan to sell its consumer health business, which includes brands such as Seven Seas vitamins and could be worth around $4.5 billion.